JP2019520316A5 - - Google Patents

Download PDF

Info

Publication number
JP2019520316A5
JP2019520316A5 JP2018556446A JP2018556446A JP2019520316A5 JP 2019520316 A5 JP2019520316 A5 JP 2019520316A5 JP 2018556446 A JP2018556446 A JP 2018556446A JP 2018556446 A JP2018556446 A JP 2018556446A JP 2019520316 A5 JP2019520316 A5 JP 2019520316A5
Authority
JP
Japan
Prior art keywords
bdca2
seq
amino acid
concentration
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018556446A
Other languages
English (en)
Japanese (ja)
Other versions
JP7045327B2 (ja
JP2019520316A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/029802 external-priority patent/WO2017189827A1/en
Publication of JP2019520316A publication Critical patent/JP2019520316A/ja
Publication of JP2019520316A5 publication Critical patent/JP2019520316A5/ja
Priority to JP2022043702A priority Critical patent/JP2022084782A/ja
Application granted granted Critical
Publication of JP7045327B2 publication Critical patent/JP7045327B2/ja
Priority to JP2024001801A priority patent/JP2024038308A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018556446A 2016-04-28 2017-04-27 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン Active JP7045327B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022043702A JP2022084782A (ja) 2016-04-28 2022-03-18 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン
JP2024001801A JP2024038308A (ja) 2016-04-28 2024-01-10 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662328959P 2016-04-28 2016-04-28
US62/328,959 2016-04-28
PCT/US2017/029802 WO2017189827A1 (en) 2016-04-28 2017-04-27 Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022043702A Division JP2022084782A (ja) 2016-04-28 2022-03-18 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン

Publications (3)

Publication Number Publication Date
JP2019520316A JP2019520316A (ja) 2019-07-18
JP2019520316A5 true JP2019520316A5 (https=) 2020-05-14
JP7045327B2 JP7045327B2 (ja) 2022-03-31

Family

ID=58672794

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018556446A Active JP7045327B2 (ja) 2016-04-28 2017-04-27 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン
JP2022043702A Pending JP2022084782A (ja) 2016-04-28 2022-03-18 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン
JP2024001801A Pending JP2024038308A (ja) 2016-04-28 2024-01-10 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022043702A Pending JP2022084782A (ja) 2016-04-28 2022-03-18 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン
JP2024001801A Pending JP2024038308A (ja) 2016-04-28 2024-01-10 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン

Country Status (14)

Country Link
US (2) US20190284281A1 (https=)
EP (1) EP3448425A1 (https=)
JP (3) JP7045327B2 (https=)
KR (5) KR20240033168A (https=)
CN (2) CN109475623B (https=)
AU (2) AU2017258191B2 (https=)
CA (1) CA3022116A1 (https=)
CO (1) CO2018012506A2 (https=)
EA (1) EA201892443A1 (https=)
IL (2) IL262514B2 (https=)
MA (1) MA44763A (https=)
MX (3) MX2018012945A (https=)
PH (1) PH12018502278A1 (https=)
WO (1) WO2017189827A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019040671A1 (en) * 2017-08-22 2019-02-28 Biogen Ma Inc. METHODS OF PURIFYING ANTIBODIES HAVING REDUCED AGGREGATES OF HIGH MOLECULAR WEIGHT
EP3823594B1 (en) 2018-07-19 2025-02-05 Ichnos Sciences S.A. Liquid antibody formulation
KR200494676Y1 (ko) 2020-08-04 2021-12-01 (주) 티나인 버튼식 헤어 염색기
CA3203971A1 (en) 2020-12-03 2022-06-09 Biogen Ma Inc. Methods of treating cutaneous lupus erythematosus and systemic lupus erythematosus
EP4385525A1 (en) 2021-08-09 2024-06-19 Inventera Inc. Nanostructure excreted in urine through kidney without being phagocytosed and/or metabolized by macrophage after in vivo injection
TW202400652A (zh) * 2022-05-25 2024-01-01 大陸商映恩生物製藥（蘇州）有限公司 抗ｂｄｃａ２抗體及其用途
CN120475994A (zh) * 2022-12-28 2025-08-12 映恩生物科技(上海)有限公司 抗bdca2抗体-药物偶联物及其用途
WO2025067469A1 (zh) * 2023-09-28 2025-04-03 南京维立志博生物科技股份有限公司 Bdca2单克隆抗体及其和taci组成的融合蛋白及其方法和用途
WO2026008012A1 (zh) * 2024-07-04 2026-01-08 杭州博之锐生物制药有限公司 抗bdca2抗体及其用途
CN118638234B (zh) * 2024-07-04 2025-10-14 杭州博之锐生物制药有限公司 抗bdca2抗体及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1798575A (zh) * 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
CN111961134B (zh) * 2012-12-10 2024-04-05 比奥根Ma公司 抗血液树突细胞抗原2抗体及其用途

Similar Documents

Publication Publication Date Title
JP2019520316A5 (https=)
US7785595B2 (en) Stabilized anti-hepatitis B (HBV) antibody formulations
JP2016535020A5 (https=)
JP2018162295A (ja) 医薬製剤
RU2021137159A (ru) Стабильные водные составы на основе антител
JP2017160208A5 (https=)
RU2017111228A (ru) Композиции антитела против IL-7R
RU2017131618A (ru) Стабильный жидкий состав для моноклональных антител
JP2007532660A (ja) 抗−ｉｌ−９抗体製剤及びその使用法
JP2014514346A5 (https=)
RU2018107725A (ru) Стабильный состав на основе антитела к ifnar1
JP2017537105A5 (https=)
IL274846B2 (en) Formulation for anti-alpha 4 antibody in cell 7
JP2018511609A5 (https=)
JP2008528638A5 (https=)
JP2019510739A5 (https=)
RU2018100824A (ru) Антитела, которые связываются с сортилином и подавляют связывание програнулина
JP2018515493A5 (https=)
RU2014101207A (ru) Новые показания к применению при лечении антителами против il-1-бета
EA031489B1 (ru) Способ лечения ревматоидного артрита
JP2018529635A5 (https=)
JP7398958B2 (ja) 安定的抗ｏｓｍｒ抗体製剤
JP7467438B2 (ja) 抗ｒｓｖ抗体の製剤及びその使用方法
IL240695B1 (en) NME inhibitors and methods of using NME inhibitors
JP2018529661A5 (https=)